Objectives: The lack of a suitable sham condition for repetitive transcranial magnetic stimulation (rTMS) research may compromise the success of blinding procedures. The aim of this systematic review was to examine the reporting of blinding success in randomised sham-controlled trials (RCTs) of rTMS applied to the dorsolateral prefrontal cortex.
Methods: A literature search using Pubmed and Web of Science was conducted to identify RCTs of rTMS. Regression analyses were used to investigate whether participants in the real and sham rTMS groups differed in (1) their ability to correctly guess to which intervention they had been randomised, and (2) how likely they were to think they had received real rTMS.
Results: Thirteen out of 96 (13.5%) RCTs reported blinding success. Available data from 9/13 studies showed that participants in real and sham rTMS groups were not significantly different in their ability to correctly guess their intervention allocation, but with a trend for participants in the real group to more often guess correctly. However, people in the real rTMS groups were significantly more likely to think they had received real rTMS compared with those in sham rTMS groups.
Conclusions: Few RCTs in rTMS report on blinding success. As current sham methods may inadequately mimic real rTMS, this could result in only partial success of blinding and bias estimations of treatment effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/15622975.2010.541281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity.
View Article and Find Full Text PDFUnlabelled: Early phase dose-finding (EPDF) trials are key in the development of novel therapies, with their findings directly informing subsequent clinical development phases and providing valuable insights for reverse translation. Comprehensive and transparent reporting of these studies is critical for their accurate and critical interpretation, which may improve and expedite therapeutic development. However, quality of reporting of design characteristics and results from EPDF trials is often variable and incomplete.
View Article and Find Full Text PDFPowerful generative AI models of protein-ligand structure have recently been proposed, but few of these methods support both flexible protein-ligand docking and affinity estimation. Of those that do, none can directly model multiple binding ligands concurrently or have been rigorously benchmarked on pharmacologically relevant drug targets, hindering their widespread adoption in drug discovery efforts. In this work, we propose FlowDock, the first deep geometric generative model based on conditional flow matching that learns to directly map unbound (apo) structures to their bound (holo) counterparts for an arbitrary number of binding ligands.
View Article and Find Full Text PDFMachine learning and AVO class II workflow for hydrocarbon prospectivity in the Messinian offshore Nile Delta Egypt.
Sci Rep
January 2025
Rashpetco Company, Cairo, Egypt.
This study presents a comprehensive workflow to detect low seismic amplitude gas fields in hydrocarbon exploration projects, focusing on the West Delta Deep Marine (WDDM) concession, offshore Egypt. The workflow integrates seismic spectral decomposition and machine learning algorithms to identify subtle anomalies, including low seismic amplitude gas sand and background amplitude water sand. Spectral decomposition helps delineate the fairway boundaries and structural features, while Amplitude Versus Offset (AVO) analysis is used to validate gas sand anomalies.
View Article and Find Full Text PDFComparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.
Ann Rheum Dis
January 2025
Rheumatology Center, Toulouse University Hospital, Toulouse, France.
Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).
Methods: The Strategies for glucocorticoid TApering in Rheumatoid arthritis (STAR) study was a double- blind, double-placebo randomised controlled trial including patients with RA receiving a stable dose of glucocorticoid 5 mg/day for ≥3 months and were in LDA for ≥3 months. Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before discontinuation or to taper prednisone by 1 mg/day every month until complete discontinuation, contingent on maintaining LDA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!